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Abstract: 
Phosphoenolpyruvate carboxykinase (PEPCK) is the metabolic enzyme that catalyzes the first 
committed step in gluconeogenesis and glyceroneogensis.  More recently, PEPCK has been 
implicated in the maintenance and establishment of infections in macrophages by 
Mycobacterium tuberculosis, cancer cell growth and metabolic homeostasis, and overall TCA 
cycle flux as a moderator through removal of cycle anions. Many isoforms of PEPCK have been 
structurally and kinetically characterized against many different inhibitors.  Of these inhibitors, 
3-mercaptopincolinic acid (3-MPA) was shown to bind allosterically (Ki ~ 150µM) in an allosteric 
cleft behind the nucleotide binding pocket, as well competitively in the OAA/PEP binding site (Ki 
~ 5µM). A new inhibitor, 3-carboxymethylthio-picolinic acid (CMP), has been designed based on 
of the structure of 3-MPA and other inhibitory studies by Stiffin et al (2009) in order to create a 
more selective inhibitor for PEPCK’s active site.  Previous studies mapping the active site of 
GTP-dependent PEPCKs has shown an overlapping secondary binding site adjacent to the 
competitive binding cleft.  CMP has been designed from the previous 3-MPA molecule scaffold 
but with a simple carboxymethyl tail modification to simultaneously occupy the overlapping 
site.  This study will investigate the structural and kinetic repercussions of the binding of CMP to 
three isozymes of PEPCK; PEPCK from Mycobacterium tuberculosis, rat cytosolic PEPCK, and 
finally human mitochondrial PEPCK.  The data from the structural crystallographic studies of 
CMP and rat cytosolic PEPCK, it is shown that CMP does in fact occupy both the competitive site 
in coordination with the manganese ion but also extends into the overlapping adjacent pocket 
as intended.  The kinetic results of CMP against the three isozymes in the catalytic direction of 
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PEP production shows an Ki ~ 30-90uM.   These two results furthermore show that the adjacent 
binding cleft can be utilized for future, more selective, inhibition of GTP-dependent PEPCK.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Acknowledgements: 
I would like to start off thank my family, Karen and Art McLeod and my brother Mike.  Without 
their teaching and dedication to my growth I would not be in the position that I am today.   
Thank you to Will Lotosky for introducing me into the lab during my undergraduate degree and 
fostering my drive for knowledge and understanding.   Thanks to Marcia Chaudet for being a 
great resource when helping me with all structural biology related problems, and staying up 
late collecting data.  Thanks to Iain Wallace and the rest of the Holyoak lab members, past and 
present, for keeping me sane and allowing me to truly enjoy my experience through my 
Masters.   Thank you to all of my friends and colleagues I have gained through my time at grad 
school, I will cherish the memories we have created. Thank you to both Dr. Brendan McConkey 
and Dr. David Rose for guidance and help throughout my degree, as well as being a part of my 
committee.  
Finally, thank you to Dr. Todd Holyoak.  You’re mentoring and fostering of me has allowed me 
to become the scientist I am today.   
 
 
 
 
vi 
 
Table of Contents  
Author’s Declaration…………………………………………………………………………………………………………………ii 
Abstract…………………………………………………………………………………………………………………………………….iii 
Acknowledgements…………………………………………………………………………………………………………………..v 
List of Figures………………………………..………………………………………….……………………………………….……..x 
List of Tables……………………………………………………………………………………………………………………………xii 
List of Equations……………………………………………………………………………………………………………………..xiii 
List of Abbreviations……………………………………..…………………….………………………………………………..xiv 
 
Introduction…………………………………………………………………………………….…..1 
Part 1: PEPCK’s Isozymes 
1.1: History and Characterization of Phosphoenolpyruvate carboxykinase                          1 
1.2: Nucleotide Specificity                                1 
1.3: Compartmental Specificity                               7 
1.4: Gene Loci of Compartmental Isozymes                              8 
 
Part 2: Regulation and Expression                   
2.1: Lysine Acetylation                                          9 
2.2: Hormonal & Small Molecule Control                             9 
2.3: Methylation                               12 
2.4: DNase 1 Hypersensitivity                              13 
Part 3: Metabolic Function and Biomedical Implications 
3.1: Functional Role                               14 
vii 
 
3.2: The Citric Acid Cycle                              14 
3.3: Diabetes and Glucose Homeostasis                              16 
3.4: Mycobacterium tuberculosis Infections                            17 
3.5: Cancer                                18 
3.6: Aging                                 19 
 
Part 4: Enzyme Structure and Catalysis 
4.1: Introduction to Catalysis                               20 
4.2: General Structure/Sequence Similarity                            22 
4.3: Gross Architecture of PEPCK                             22 
4.4: Dynamic Mobile Motifs & Structural Characteristics                           25 
 
Part 5: Catalysis & Reaction Mechanism 
5.1: Holo-enzyme                               28 
5.2: Binding of Substrates – R-Loop & OAA                            30 
5.3: Binding of Substrates – P-Loop & GTP                            32 
5.4: The Omega Loop Closure                              34 
5.5: Catalysis                                 36 
5.6: Product Release                               36 
 
Hypothesis…………………………………………………………………………….……………38 
 
 
 
viii 
 
Materials and Methods………………………………………………………………...……39 
Part 7: Protein Expression and Purification 
7.1: Expression of Isozymes rcPEPCK & mtbPEPCK                                       39 
7.2: Expression of hmPEPCK                              39 
7.3: rcPEPCK Purification for Kinetics and Crystallography                          40 
7.4: mtbPEPCK Purification for Kinetics                             41 
7.5: hmPEPCK-SUMO Fusion Purification for Kinetics                           41 
7.6: hmPEPCK Purification – Cleaved                                          42 
 
Part 8: Kinetic Assays 
8.1: PEP  OAA – Dephosphorylation and Carboxylation                           45 
8.2: IC50 Determination                               45 
8.2: Data Analysis                               46 
 
Part 9: Structural Studies 
9.1: Crystallization of rcPEPCK                             47 
9.2: Data Collection                               47 
9.3: Determination and Refinement                             47 
 
Results………………………………………………………………………………………………..48 
Part 10: Results 
10.1: Kinetic Analysis of CMP                              48 
10.2: Purification of hmPEPCK                             49 
10.3: Structural Determination of rcPEPCK-CMP Complex                                      50 
 
 
ix 
 
Discussion…………………………………………………………………………………………..52 
Part 11: Inhibition of PEPCK 
11.1: 3-Mercaptopicolinic acid and Its History of Inhibition                           52 
11.2: Further Inhibitory Studies and Adjacent Binding Cleft                          55 
11.3: Conception of Carboxymethyl-thiol-picolinic Acid                          57 
11.4: Inhibition of PEPCK by CMP                             60 
 
Conclusion and Future Directions……………………………………………………………….………………..69 
References……………………………………………………………………………………….………………………………..…………71 
Appendix…………………...………………………………………………………………………………………………………………….76 
Equations                   76 
Rat Cytosolic Inhibition Fit to Competitive Model                           78 
Rat Cytosolic K/V Replot                              79 
Rat Cytosolic 1/V Replot                              80 
Mycobacterium Tuberculosis Inhibition Fit to Competitive Model             81 
Mycobacterium Tuberculosis K/V Replot                            82 
Mycobacterium Tuberculosis 1/V Replot                            83 
Human Mitochondrial Inhibition Fit to Competitive Model                          84 
Human Mitochondrial K/V Replot                                         85 
Human Mitochondrial 1/V Replot                                         86 
IC50 3-MPA Inhibition of Human Mitochondrial PEPCK                          87 
IC50 CMP Inhibition of Human Mitochondrial PEPCK                          88 
IC50 CMP Inhibition of Rat Cytosolic PEPCK                            89 
rcPEPCK_CMP Structural Data Table                             9 
x 
 
List of Figures 
Figure 1.1 – Structural alignment of ATP- and GTP-dependent nucleotide binding pockets          3 
Figure 1.2 – GTP binding pocket with GTP bound                                         4 
Figure 1.3 – ATP binding pocket with ATP bound                             5 
Figure 1.4 – Binding schematic of ATP- and GTP-binding pockets with nucleotides bound            6 
Figure 2.1 – Cytosolic PEPCK gene with genomic regulators from Yang et al 2009 review           11                      
Figure 3.1 – Scheme of TCA cycle and PEPCK involvement             15 
Figure 4.1 – Reaction mechanism of PEPCK                                   21 
Figure 4.2 – Two major domains of PEPCK                            24 
Figure 4.3 – Mobile loop elements of PEPCK active site             27 
Figure 5.1 – M1 Manganese bound to active site              29 
Figure 5.2 – Catalytically competent conformation of OAA             31 
Figure 5.3 – Catalytically incompetent conformation of OAA            31 
Figure 5.4 – GTP-nucleotide binding pocket               33 
Figure 5.5 – GTP in coordination with M2 cation                           33 
Figure 5.6 – Omega loop and R loop locking orientation                          35 
Figure 5.7 – Michaelis complex with all mobile motifs in ordered position                         35 
Figure 5.8 – Reactive enolate and CO2                                        37 
Figure 5.9 – Two conformers of Y235                             37 
Figure 10.1: SDS-PAGE of hmPEPCK purification                           49 
Figure 10.2: CMP bound to rcPEPCK active site                                              51 
xi 
 
Figure 11.1 – 3-mercaptopicolinic acid bound to active site                          54 
Figure 11.2 – Sulfoacetate bound to active site                           56 
Figure 11.3 – 3-mercaptopicolonic acid and sulfoacetate bound to active site                         58 
Figure 11.4 – Various inhibitors of PEPCK                            59 
Figure 11.5 – Structural overlap of rcPEPCK-CMP and rcPEPCK-MPA                        62 
Figure 11.6 – rcPEPCK-CMP Binding Residues                           63 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
List of Tables  
Table 1.1 – Compartmental isozyme distribution across different species                          8 
Table 7.1 – Purification buffers for kinetic purification protocols                              42 
Table 7.2 – Purification buffers for hmPEPCK                           44 
Table 10.1 – Kinetic Characterizations of CMP and PEPCK                          48 
Table 10.2 – IC50 Characterizations                             48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Equations 
Equation 12.1 – Gibbs Free Energy                                         76 
Equation 12.2 - Determination of IC50                             76 
Equation 12.3 – Determination of Ki from IC50 to Fit Competitive Model                        76 
Equation 12.4 – Competitive Inhibition Model                           76 
Equation 12.5 – Michaelis Menten Equation                                        77 
 
 
 
 
 
 
 
 
 
 
xiv 
 
List of Abbreviations: 
PEPCK – Phosphoenolpyruvate carboxykinase 
rcPEPCK – Rat cytosolic Phosphoenolpyruvate carboxykinase 
hmPEPCK – Human mitochondrial Phosphoenolpyruvate carboxykinase 
mtPEPCK – Mycobacterium tuberculosis Phosphoenolpyruvate carboxykinase 
GTP – Guanosine-5’- triphosphate 
GDP – Guanosine-5’- diphosphate 
ATP – Adenosine-5’- triphosphate 
3-MPA – 3-Mercaptopicolinic acid 
CMP – 3-carboxymethyl-thio-picolinic acid 
DTT – 1,4-dithiothreitol 
TCEP – Tris-2-carboxyethyl-phosphine 
OAA – Oxaloacetic acid 
PEP – Phosphoenolpyruvate 
IPTG – Isopropyl β-D-1-thiogalactopyranoside 
βSP – 3-Sulfopyruvate 
HEPES – 4-(2-hydroxyethyl)-1-poperazineethanesulfonic acid 
ITP – Inosine-5’- triphosphate 
PEG – Polyethylene glycol 
TCA – Tricarboxylic acid cycle
1 
 
Introduction - Part 1: Isozymes of PEPCK 
1.1: History and Characterization of Phosphoenolpyruvate 
carboxykinase 
The story of Phosphoenolpyruvate carboxykinase (PEPCK) was started in the 1950’s with Utter 
and Kurahashi from Case Western University where they initially characterized the enzyme  
which they named oxaloacetate carboxylase.62  In Utter and Kurahashi’s mini-series, they 
outlined and documented PEPCK’s nucleotide requirement as well as some mechanistic 
features of the catalysis of the enzyme, mainly the decarboxylation and subsequent 
phosphorylation of oxaloacetic acid (OAA) to form carbon dioxide and phosphoenolpyruvate.62 
From these mechanistic findings an entire subsect of enzymology and metabolomics with 
regards to PEPCK has been created, led by the late Dr. Richard Hanson.  From the identification 
of PEPCK until now, a great deal is understood behind the reaction mechanism and 
requirements of various PEPCK isozymes.  Even with 70 years of research focused on PEPCK, 
there may be a misunderstanding and underappreciated role of PEPCK in general TCA cycle 
flux/metabolism that has only recently begun to be elucidated.  
 
1.2: Nucleotide Specificity 
Referring back to Utter and Kurahashi, they determined that PEPCK purified from chicken liver 
had a nucleotide specificity of both ATP and/or ITP, although it is now known that chicken 
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PEPCK is GTP-dependent isozyme.62 From this initial groundwork, it was determined that PEPCK 
has a nucleotide specificity where it can utilize either ATP or GTP, but not both.  ITP, a third 
nucleotide triphosphate, can be substituted for GTP because of its pyrimidine ring carbonyl 
group coordinating with backbone amines of asparagine and phenylalanine in the active site.   
The structural differences between the two nucleotide specific classes of PEPCK can be seen 
within their respective nucleotide binding pockets. Figure 1.1 shows a structural alignment of 
the nucleotide binding cleft from submitted crystallographic structures from Escherichia coli 
(ATP-dependent) and Rattus norvegicus (GTP-dependent).  In conjunction with this alignment, 
Figures 2 and 3 show the GTP and ATP binding pockets with their nucleotides bound.  Finally 
Figure 4 shows the binding schematics from the crystallographic structures, highlighting distinct 
interacting residues.  Recently, an inorganic pyrophosphate utilizing PEPCK was characterized 
from the parasite Entamoeba histolytica.11 More work must be done to being to make 
conclusions about evolutionary phylogeny, and mechanistic properties of the unique 
pyrophosphate PEPCK. 
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Figure 1.1: Alignment of PDB ID 1OS1 (purple/Escherichia coli) and 4WY9 (tan/Rattus norvegicus).  As 
seen, there are major differences in the overall architecture of the nucleotide binding pocket of GTP and 
ATP dependent isozymes.  Figure is coloured by atom type, oxygen (red), nitrogen (blue), phosphorous 
(orange), magnesium (light green), manganese (dark green).   
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Figure 1.2: GTP binding pocket of Rattus norvegicus PEPCK with GTP bound.  The image was generated 
from PDB ID#4YW9.  Purple atoms are manganese.  Residues labelled are all residues interacting with 
the nucleotide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: ATP binding pocket of Escherichia coli PEPCK with ATP bound.  The image was generated from 
PDB ID#1OS1.  Residues labelled are all residues interacting with the nucleotide. The green atoms 
indicate calcium ions. 
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Figure 1.4: Binding schematic for nucleotide binding site A) ATP- B) GTP-dependent PEPCK.  ATP binding 
cleft of Escherichia coli (PDB ID#1OS1).  Figure 2B represents the binding schematic for GTP in nucleotide 
cleft of Rattus norvegicus (PDB ID#4YW9) 
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1.3: Compartmental Specificity 
A comprehensive review from Hanson and Garber (1972) recap work done by many different 
research groups highlighting the isozymes of PEPCK.20 Chang et al (1966) initially purified 
mitochondrial PEPCK which has a similar molecular weight as the cytosolic isoform that Ballard 
and Hanson purified three year later. 5,10 This solidified the idea that PEPCK exists in higher 
order mammals as compartmental isozymes, both mitochondrial and cytosolic. The role and 
implications of having two compartmental isozymes in higher mammals is still under 
investigation because of a lack of biochemical analysis of the mitochondrial isozyme.  This lack 
of information is a result of organismal differences in the distribution of the two 
compartmental distinct isozymes.  Referring to Table 1.1 it can be seen there is large variability 
in this relative distribution, while the traditional mouse model has a much greater amount of 
cytosolic PEPCK in relation to the mitochondrial isozyme.20  To further impact this distribution 
problem, different tissues within an organism can have different ratios of compartmental 
PEPCK.20  To date, one theory is that mitochondrial PEPCK maintains redox balance by forgoing 
transport of reducing equivalents across the mitochondrial membrane, by participating in lactic 
acid metabolism. Lactate is a common by-product of sustained physical activity.  Birds, which 
typically undergo longer periods of labourous physical activity have >90% abundance of 
mitochondrial PEPCK.20 The interplay between the two distinct compartmental isozymes has 
not been fully clarified.  In knock out studies using a mouse model, global ablation of cytosolic 
PEPCK caused major citric acid cycle flux dysregulation and eventual death.18 Mendes-Lucas et 
al created a second rat strain in which cytosolic PEPCK was knocked out, but mitochondrial 
PEPCK was overexpressed to physiologically relevant levels of the cytosolic isozyme.  The result 
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was incomplete reestablishment of metabolic homeostasis.  This was interpreted as the 
compartmental isozymes having independent control over citric acid cycle flux and PEP 
production.38 
 
Table 1: Activity distribution of total PEPCK separated into compartmental isozymes in various different 
organisms from Hanson & Garbers review. 
 
 
 
 
 
 
 
 
 
1.4: The Gene Loci of Compartmental Isozymes 
As highlighted above, the two compartmental isozymes found within higher order mammals 
although indistinct in their catalysis have unique distributions across species.  Interestingly, 
these two homologous genes are found on two different chromosomes, and are under different 
regulatory control.  Cytosolic PEPCK is found on chromosome 14, while the mitochondrial form 
is found on chromosome 20.40 This further reinforces the idea that these two isozymes function 
independently.   
 
Distribution of PEPCK Isozymes Across Different Species 
Species Mitochondrial Cytosolic 
Human 60 40 
Guinea pig 60 40 
Cow 50 50 
Sheep 35 65 
Cat 65 35 
Hamster 5 95 
Rat 10 90 
Mouse 10 90 
Rabbit 95 5 
Pigeon 95 5 
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Introduction – Part 2: Regulation and Expression 
2.1: Lysine Acetylation 
More recently, cytosolic PEPCK has been shown to be susceptible to post-translational 
modifications through lysine acetylation which has a direct impact on PEPCK at an enzymatic 
level.23,34 Increased acetylation caused increase interactions with UBR5 ubiquitin ligase, leading 
to ubiquitination and subsequent recycling of PEPCK by the proteasome.23 Lysine acetylation is 
the only known post-translational modification that regulates cytosolic PEPCK, all other 
regulation is at the genomic level. In March of 2016, a new study investigated Sirt2, a 
deacetylase determined to be specific for PEPCK by the Jiang 2011 study.  It was found that 
Sirt2 has no interaction with the acetylated lysines of PEPCK, highlighting a need for more 
studies to elucidate lysine acetylation as a regulatory mechanism of PEPCK and raising the 
question if lysine acetylation is indeed a mechanism of PEPCK regulation in vivo.28 
 
2.2: Hormonal & Small Molecule Control 
PEPCK’s role within metabolic homeostasis as a whole implies a tight control over its expression 
and regulation.  There has been an influx of recent work investigating the regulation of these 
enzymes.  It appears that the general consensus is each tissue reacts differently to various 
regulators of PEPCK expression.  PEPCK’s regulation of expression of starts during development, 
where PEPCK must be upregulated for the newborn to survive in the early stages of infancy.3 
Total knockout studies showed that mice without PEPCK were severely hypoglycemic eventually 
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resulting in death.49 Most of the regulation of PEPCK has been focused on the cytosolic isozyme, 
although there are distinct differences in the expression of the cytosolic and mitochondrial 
isozymes.  For example, the cytosolic isozyme has a half life of 6 hours and is 
environmentally/hormonal regulated, while the mitochondrial isoform is constitutively 
expressed with a half life of 60 hours.60 Hanson and colleagues did a review on the regulation of 
cytosolic PEPCK, and the general result is that the gene is tightly regulated by a plethora of 
variables on a transcriptional level, such as cAMP, glucocorticoids, and pH/metabolic acidosis 
(Figure 2.1).12,27,44   
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Figure 2.1: Cytosolic PEPCK gene from Yang et al 2009 review. Highlights all regulatory elements of the 
gene on various loci. The yellow regions are overlapping binding sites for various regulators.   
This image/research was originally published in The Journal of Biological Chemistry.  Yang, J., Reshef, L., 
Cassuto, H., Aleman, G., & Hanson, RW. Aspects of the Control of Phosphoenolpyruvate Carboxykinase 
Gene Transcription. The Journal of Biological Chemistry.  2009. 284: 27031-27035. © the American 
Society for Biochemistry and Molecular Biology. 
 
 
 
 
 
 
 
 
 
 
12 
 
These modifiers include cAMP, a marker of higher metabolic requirements, where 
administration causes a 5-8 fold increase in mRNA within 20 minutes.29  This phenomenon was 
followed by a marked decrease in PEPCK mRNA levels, which was attributed to a reflexive 
glucocorticoid response inducing insulin secretion.29   The effect of insulin on transcription 
levels was further reinforced a year later when Granner and his colleagues showed insulin, at 
physiologically relevant concentrations, inhibits transcription of PCK1, the gene of the cytosolic 
PEPCK.17  The most recent publication from Seenappa et al showed that Genistein, a soy bean 
isoflavone, acts by destabilizing cytosolic PEPCK mRNA, leading to decrease activity of the 
enzyme.48  There is very little regulation directly on PEPCK’s activity, with administration of 
Bt2cAMP causing an acute 3-fold increases in activity.46  
 
2.3: Methylation  
Benvenisty et al (1985) investigated the tissue specific methylation of PCK1 and found that 
there is a correlation with decreased methylation of PEPCK and increased rates of 
transcription.16 Along with gene methylation, the histones associated with PCK1 chromatin 
have shown to be regulated through arginine methylation.  Insulin was shown to stimulate a 
2.5-fold increase in histone H3 dimethylation, indicating a decrease in transcription.19 
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2.4: DNAse 1 Hypersensitivity 
Many groups have investigated various DNase 1 hypersensitive regions along the gene 
promoter region for PEPCK.  The DNase 1 hypersensitive sites are hallmark regulatory gene 
sequences that denote actively transcribed genes as they are revealed once chromatin 
remodelling occurs.  They also indicate tissue specific regulation, as particular hypersensitive 
sites are found only in one tissue, for example site A (-4800bp) being liver specific.66 This finding 
further reinforces differential PCK1 gene expression in tissues. 
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Introduction – Part 3: Metabolic Function and Biomedical Implications 
3.1: Functional Role 
Even though PEPCK has been studied for 70 years, the functional role of this enzyme in 
metabolism is still misunderstood.  When parsing through textbooks PEPCK is solely referred to 
as a gluconeogenic enzyme.  Although its catalysis marks the first committed step in 
gluconeogenesis, this is not the only role of PEPCK.  PEPCK’s has a cataplerotic function for the 
citric acid cycle, by removing intermediates. 
 
3.2: The Citric Acid Cycle 
The citric acid cycle is an aerobic metabolic process in the mitochondria that recycles acetyl-
CoA through conversion into various intermediates.  Acetyl-CoA is originally obtained through 
various processes from substrates that include amino acids, carbohydrates, and lipids.  Each 
turn of the cycle yields 3 NADH2, 1 FADH2, and 1 GTP molecule.1 PEPCK acts by removing citric 
acid anions, as oxaloacetate, for the conversion of PEP.1  In this, PEPCK acts as a moderator of 
the citric acid cycle by maintaining a constant flux.  PEP can then be used for a variety of 
functions required for the cell, from biosynthesis of serine and small amino acids, to the 
production of glycerol for glyceroneogenesis.  PEPCK flux to create PEP can also feed back into 
the citric acid cycle by creating acetyl-CoA through pyruvate synthesis and subsequent 
oxidation (Figure 6).  These functional roles of PEPCK show themselves very clearly with recent 
literature highlighting various medical maladies and PEPCK’s role in them. 14,15,31,36,39,64,67  
15 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Schematic representation adapted from Yang, Kalhan, and Hanson review.  Indicates where 
compartmental isozymes function with regards to the TCA cycle, and the various outcomes of PEP. 
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3.3: Diabetes and Glucose Homeostasis 
Diabetes and dysregulation of glucose homeostasis has been the primary medical ailment 
related to PEPCK because of its function in gluconeogenesis.  Besides PEPCK’s role in glucose 
production, a new role of the mitochondrial enzyme has been elucidated.  Insulin secretion was 
initially thought to be solely coupled with the generation of ATP in beta islet cells.52 In this 
model, as glycolysis and the TCA cycle turnover, ATP is generated creating a higher ratio of 
ATP/ADP.  This influx of ATP causes KATP voltage gated channels to open, creating depolarization 
and release of insulin.52 Mice with this KATP channel knocked out still have glucose stimulated 
insulin secretion (GSIS), showing this isn’t the only mechanism for insulin secretion.59 Stark and 
his colleagues recently found a correlation with mitochondrial PEPCK flux and GSIS.  It was 
proposed that mitochondrial GTP (mtGTP), produced by GTP dependent - succinyl CoA synthase 
(SCS-GTP) is a metric for TCA cycle flux.53 PEPCK utilizes mtGTP to produce PEP which has been 
proposed to induce insulin secretion.56 
Many groups have done knockout studies in mice to determine the role of PEPCK in 
gluconeogenesis, and therefore diabetes.  Stark and her colleagues investigated mitochondrial 
PEPCK via silencing.  They found these deficient mice had lower plasma glucose, 
triacylglycerides, fat mass, with raised lactate levels.51 This silencing hindered gluconeogenesis, 
but it appeared that the cytosolic isoform had partial compensation.51 The overall effect on 
homeostasis may be quite different in organisms with different distribution of the two 
isoforms.51 
17 
 
Many studies with cytosolic PEPCK knock outs have been completed.  These studies show the 
ability for the kidney to take over gluconeogenic function from hepatic knockouts.49 But whole 
body knock outs resulted in hypoglycemia and death of the mice in approximately 2 days.49 
Other studies indicated that PEPCK’s role is not solely gluconeogenic.  One such knock out study 
with hepatic cytosolic knock out mice resulted in extremely fatty livers.  Hakimi et al showed 
that this lipid deposition indicates that cytosolic PEPCK isn’t only involved with 
gluconeogenesis.  There conclusion was that without cytosolic PEPCK, major TCA and 
mitochondrial dysfunction occurred.7,18  
 
3.4: Metabolic Function – Mycobacterium tuberculosis Infections 
Early in 2010, a new link between Mycobacterium tuberculosis infection and PEPCK was 
established.  Marrero et al, with the knowledge that M. tuberculosis utilize fats as a primary 
carbon source, target PEPCK to see the effect of various knock outs and silencing.  They found 
that M. tuberculosis strains deficient in PEPCK could not establish infections in macrophages or 
mice hosts.36 Secondly, M. tuberculosis that had already established a chronic infection 
required PEPCK for persistence.  Silencing of PEPCK resulted in the clearance of the infection.36 
These findings show a potential therapeutic target for the treatment of multi-drug resistant 
tuberculosis infections.   
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3.5: Metabolic Function – Cancer 
In 2014, an initial paper relating mitochondrial PEPCK to cancer was released by Mendez-Lucas 
and his colleagues.39 Since then, a flurry of papers investigating this relationship has come to 
light.  Cancer cells have adopted a unique metabolism that is specialized to the particular 
cancer type, but it has allowed these cells to be highly adaptive to their environment.  Mendez-
Lucas first initially showed that PCK2, the gene for mitochondrial PEPCK, was upregulated in 
many stress pathways that cancer cells typically utilize for survival.38 Li and her colleagues 
started the influx of insight into cancer metabolism of PEPCK, with a first conclusion that PCK1 
is upregulated in stem-cell like cancer cells, and possibly undifferentiated cells.33 
In 1925, Otto Warburg came to the conclusion that cancer cells adopt a unique metabolism 
where they undergo aerobic glycolysis.65   This metabolism will greatly utilize glucose to have 
high glycolytic flux.  In the end of glycolysis, PEP is catalyzed by pyruvate kinase to yield 
pyruvate, which feeds into the TCA cycle.  A new theory proposed by Vincent et al (2015) is that 
once glucose is consumed in the tumor microenvironment, cancer cells will change their 
metabolism and focus flux through PEPCK, thus filling the high demand for PEP.64 The lack of 
environmental glucose and change in primary metabolism leads to an upregulation of 
expression of mitochondrial PEPCK.  This high flux may be attributed to a phenomena called 
glutamine addiction, where cancer cells utilize increased amount of glutamine.15 This glutamine 
is converted into α-ketoglutarate which then fuels the TCA cycle.    
PEPCK has also been implicated in chemoradiation susceptibility in colorectal cancer cell lines.42 
5-Flurouracil is a common therapeutic agent that inhibits thymidylate synthase, an enzyme that 
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produces thymidine for DNA synthesis and replication.  A link was found between 
downregulation of mitochondrial PEPCK and 5-Flurouracil resistance, although no clear 
mechanism was deduced.42 
Finally, Leithner et al in 2014 showed inhibition of PEPCK through treatment of 3-
mercaptopicolinic acid, or silencing of PCK2 by siRNA significantly increased apoptosis of 
various lung cancer cell lines.  This increase in apoptosis occurred in glucose deprived 
environments, while it was ineffective in media where glucose was in excess.31 
 
3.6: Metabolic Function – Aging 
2016 has marked a new biomedical front for PEPCK, led by the late Dr. Hanson and his 
colleagues. Aging is a deeply studied phenomenon that has recently been linked to a change in 
metabolism.  This change is away from aerobic metabolism, the utilization of the TCA cycle, to a 
mainly anaerobic glycolysis.67 This shift to anaerobic glycolysis in only further exasperated by a 
general lack of physical activity and dietary changes.  Hanson and his colleagues showed a 
reciprocal regulation between cytosolic PEPCK, and Pyruvate kinase (PK) in aging C. elegans.   In 
aged C. elegans, PEPCK was downregulated effecting TCA cycle flux, while PK was upregulated 
increasing glycolytic flux.67 
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Introduction - Part 4: Enzyme Structure and Catalysis 
4.1: Introduction to Catalysis  
As mentioned before, many characterizations have been done with regard to the various 
isozymes of PEPCK; whether ATP vs GTP dependent enzymes, or mitochondrial vs cytosolic.  
These enzymes, having the same catalytic mechanism, have very similar active sites.  In 
summary, all enzymes have a requirement for 2 divalent metal cations, substrate (either OAA 
for forward reaction, or PEP for reverse), and a nucleotide.  Many studies have been completed 
investigating the dual cation requirements of PEPCK, and there seems to be preferential metal 
cation requirements for the various isozymes across different species.  For instance, for chicken 
mitochondrial PEPCK, the most activating of the cations is one magnesium and one manganese 
ion, although iron or cobalt can substitute for manganese.30  It is thought that the initial 
magnesium cation forms a Mn2+-nucleotide complex that is activating for the enzyme, with the 
manganese for the basis for substrate binding in the active cleft.41,50 All GTP-dependent PEPCK 
enzymes also have a similar molecular weight approximating 70kDa and exist as monomers, 
while some ATP-dependent PEPCK exist as functional multimers.   The general mechanism of 
catalysis is as follows: OAA binds in octahedral coordination with metal cation in conjunction 
with nucleotide binding, decarboxylation of OAA to relinquish carbon dioxide and create a 
reactive enolate intermediate, phosphorylation of enolate by gamma-phosphate of nucleotide, 
and finally product release.  Although most characterized PEPCK’s favour decarboxylation of 
OAA, some isozymes carboxylate PEP to refill the TCA cycle.  These enzymes are generally from 
parasitic eukaryotic sources.13,14,43 
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Figure 4.1: Reaction mechanism for the forward catalysis of OAA to PEP by PEPCK.   
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4.2: General Structural/Sequence Similarity 
Structural work investigating the intricacies of PEPCK’s catalysis has been completed across 
many different species.  To date, there are 69 deposited structures with from various organisms 
such as; Rattus norveigcus, Escherichia coli, Mycobacterium tuberculosis, Homo sapiens, 
Thermus thermophiles, Gallus gallus, Anaerobiospirillum succiniciproducens, Cornyebacterium 
glutamicum, Actinobacillus succinogenes, and Trypanosoma cruzi.  These structures include 
both ATP and GTP-dependent isoforms, as well as mitochondrial and cytosolic variants. 
The overall sequence similarity between mitochondrial and cytosolic isozymes is above 60%, 
and the active site of ATP and GTP dependent isozymes are mostly conserved with the only 
differences located in the nucleotide binding cleft.22  Structural comparison revealed their 
quaternary structures are well conserved between rat cytosolic and avian mitochondrial with a 
Cα RMSD value of 0.94 Å.58  Finally there are no related protein families having related 
architecture to PEPCK, and therefore have been classified as their own PEPCK family (Pfam ID# 
PF00821).16  
 
4.3: Gross Architecture of PEPCK 
PEPCK has been categorized into two main domains; an N-terminal (residues 1-259), C-terminal 
(residues 160-622), and finally an active site placed in between the two termini.  This 
categorization was first popularized by Matte, Goldie, Sweet, and Delbaere in their 1996 paper 
highlighting the structure of Escherichia coli ATP-dependent PEPCK, Figure 4.2.37 
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Matte and his colleagues determined that these two individual domains do not fold separately 
from one another, but rather they make many passes through one another.36 These two 
domains undergo dynamic shifts during catalysis, where they rotate inwards towards the active 
site.  This movement is proposed to reduce the volume of the active site, excluding solvent 
which can pronate the reactive intermediate to produce unfavourable pyruvate.  This reduction 
in active site volume also forces the nucleotide and substrate closer to one another to position 
them for catalysis.58 
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Figure 4.2: Two major domains of PEPCK. The N-terminal domain is in green from residues 1-
259.  The C-terminal domain is in blue from residues 260-622.  Modelled enzyme is from GTP-
dependent Rat cytosolic PEPCK.  
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 4.4: Dynamic Mobile Motifs & Structural Characteristics 
For the remainder of the thesis, rat cytosolic PEPCK will be used as a reference structure unless 
otherwise stated. 
Since the initial structural characterization of Dunten in 2002 of the human cytosolic enzyme, 3 
major mobile motifs have been identified and relatively conserved in PEPCK.  These motifs 
undergo conformation changes from open-closed state that aligned substrates into 
coordination that allow for catalysis (Figure 4.3).  
The first of these dynamic elements is the R Loop, residues 85-92, which appears to interact 
directly with OAA.  A secondary purpose of the R-loop is its interaction with the Omega loop.  
This is the contact that is believed to allow for the “locking” of the omega loop over the active 
site.25 
Secondly, the P-loop is the most characterized mobile element in the active site of PEPCK.  This 
P(hosphate)-loop is kinase-1a motif, which is a common structural element in binding 
phosphate/nucleotide binding.61 The P-loop spans residues 284-292 and is responsible for 
cradling the β and γ phosphates.  Its rotation into a closed state brings the nucleotide 
triphosphate towards the M1 metal, bridging both cations together.  This movement allows for 
phosphoryl transfer onto the intermediate.  The conformation change to a closed state upon 
nucleotide binding also relieves a steric clash between A287 of the P-loop and T465 of the 
omega loop.  S286 of the P-loop has a function in substrate binding, as it interacts with O5 of 
OAA.58 The P-loop also contains a completely conserved cysteine, C288, that has been shown to 
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result in inactivation of the enzyme if altered.  This alteration could be pH dependent, 
sulfhydration, or other factors.32,62  
The final mobile element is an omega loop, which is ~10 amino acids from residues 464-474, 
that resemble the omega symbol.  This motif acts as a lid over the active site.  Once the 
Michaelis-Menten complex has formed, the loop will close to prevent unwanted protonation of 
the reaction intermediate from bulk solvent.  The omega-loop has a functional role of maintain 
the bi-lobal motion of the C- and N-terminal domains after they have rotated inward in the 
catalytically competent conformer.25 Only once the omega-loop has sampled the closed 
conformation are the substrates in an orientation that allows catalysis to occur.25  
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Figure 4.3: Various dynamic motifs of PEPCK’s active site highlighting the R-loop (red), P-loop 
(green), Omega-loop (yellow).  This structure was generated from the PDB ID#3DT2, a complex 
of rat cytosolic PEPCK with GTP and oxalate.   
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Introduction – Part 5: Catalysis and Reaction Mechanism 
5.1: The Holo-Enzyme of PEPCK 
PEPCK’s initial state prior to substrate binding is an open conformation with one of the two 
divalent metal cation required for catalysis bound to the active site.  The manganese is in an 
octahedral conformation in coordination with K244, H264, D311, and various water molecules 
to fill the rest of the occupancies (Figure 5.1).57  In the chicken mitochondrial isozyme, the 
reactive cysteine C307 (C288 in rat cytosolic PEPCK) can be shown interacting with the active 
site manganese in a tetrahedral conformation but this geometry is not seen in the rat cytosolic 
PEPCK.22  This tetrahedral geometry may represent the basis of some level of regulation, and 
may give insight into differing kinetic effects when the M1 manganese is substituted with other 
metals.22 
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Figure 5.1: Manganese M1 meta (purple)l bound in octahedral coordination from PDB ID# 
2QEW. All bonding residues; H265, K244, and D311 holding manganese in place, are 
highlighted. 
 
 
 
 
 
 
 
 
 
 
30 
 
5.2: Binding of Substrates – R-loop & OAA 
For catalysis to occur, the 3 dynamic motifs must undergo a shift from an open unordered state 
to a closed ordered state.  For this to occur, the nucleotide substrate as well as OAA/PEP must 
bind.  OAA binds with the M1 metal in two conformations, one that does not allow for catalysis 
to occur, while the other is the competent orientation (Figure 5.2 and 5.3).57 The proper 
orientation positions OAA O3 and O5 coordinated with M1.  O5 also interacts with the P-loop 
S286 while O4 interacts with R87 of the R-loop.57 In this state, O2 of OAA interacts again with 
R87’s Nε (Figure 5.2).57     
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Figure 5.2: OAA bound to M1 in catalytically competent orientation from PDB ID#2QF2.  P Loop 
(green) and R Loop (red) are labelled.   
 
Figure 5.3: OAA bound to M1 in catalytically incompetent conformation from PDB ID#2QF2.  P 
Loop (green) and R Loop (red) are labelled.   
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5.3: Binding of Substrates – P-Loop & GTP  
GTP’s guanosine base interacts in the nucleotide binding pocket through pi-stacking of Phe530 
and 517 and hydrogen bonding of Asn533 with the carbonyl O6 (Figure 5.4).5 The nucleotide 
binds to the M2 metal which supports the γ and β phosphates.  The M2 cation is stabilized in 
the active site by T291 (P-loop), while water molecules occupy the rest of the octahedral 
coordination (Figure 5.5).57 The P-loop when in ordered orientation, specifically T291 and G289, 
stabilizes the 3 phosphates which brings the nucleotide into proximity to M1 and OAA.57 The 3 
phosphate groups are orientated in an eclipsed orientation which increases the energy state of 
GTP.57 This allows for phosphoryl transfer to happen more readily.  
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Figure 5.4: GTP-nucleotide binding pocket with GTP bound from PDB ID#2QEY.  All contacting 
residues and P Loop (green) are labelled.  
 
Figure 5.5: GTP in coordination with manganese M2 metal (pink) from PDB ID#2QEY.  M2 cation 
is in octahedral coordination with T291 (P Loop) and cradling the β and γ phosphates. 
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5.4: The Omega Loop Closure  
Once the Michaelis complex has been formed and all substrates are bound the final mobile 
element, the omega loop, must close over the active site.  If one of the mobile loops, either P- 
or R-loop, is disordered it will sterically clash with the omega loop to prevent premature 
closure.25  The P- and R-loop both have direct contacts with substrates, which lend energy to 
cause the mobile elements to adopt a closed formation.24  The omega loop has to undergo a 
conformational change, but it does not directly interact with any substrates.24  The energy 
required to cause this dynamic movement to a closed state is thought to come from the other 
substrates binding to the active site.24  It is proposed that once OAA/PEP bind to the R-loop 
R87, enthalpic energy transfer is used to rotate the omega loop ~10 Å towards the active site.24  
R87 interacts with R89 to stabilize it into a conformation that allows H470 of the omega loop to 
bind, effectively “locking” the omega loop into a closed position.25   Other neighbouring 
residues, S90, R483, E469 also stabilize the closed omega loop (Figure 5.6).25 This closure shifts 
the P-loop, and therefore the nucleotide/metals (~1.5 Å) towards OAA to bring both substrates 
close enough together for in-line phosphoryl transfer (Figure 5.7).25 
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Figure 5.6: Omega loop (yellow) in closed order position contacting with R loop (purple) from 
PDB ID#2QF2.  
 
Figure 5.7: Michaelis complex with all mobile elements, R loop (red), omega loop (yellow), and P 
loop (green) in closed position. OAA is present in mesh on left, while GTP from PDB ID#2QEY in 
mesh is on right.  Structure was generated from PDB ID#2QF2. 
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5.5: Catalysis 
The first step of catalysis is the formation of the reactive enolate species.9 This occurs through a 
decarboxylation of OAA, relinquishing CO2.  The CO2 is stabilized by the rotation of Y235 (Figure 
5.8).9 Once the reactive enolate is formed, phosphoryl transfer occurs to create PEP.   
 
5.6: Product Release 
After catalysis, the energy donated from substrate binding has now been transferred.  This 
changes the omega loop back to the open conformation.9  PEP now shifts away from the M1 
metal, while T235 rotates towards the interior of the enzyme, removing its interaction with CO2 
(Figure 5.9).9  Now that PEP is not directly coordinated with the metal, PEP’s P-loop interaction 
is also gone with S286.9  This loss of interaction gives the P-loop the liberty to shift into its open 
state, moving the guanosine-3’-diphosphate and M2 away from M1.9  With the omega loop and 
P-loop now in open states, both CO2 and PEP are released.   
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Figure 5.8: An alignment highlighting enolate intermediate coordinating with manganese M1 
metal (purple) and CO2 (modelled in mesh) from PDB ID#2QF2.  Overall structure with Y235 in 
stabilizing conformation is from PDB ID#2RK8. 
 
 
 
Figure 5.9: An alignment from PBD ID#2RK8 (tan) and PDB ID# 2QEW (light green) highlighting 
the two conformations of Y235.  
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Hypothesis 
CMP will be utilized to study its potential as an inhibitor against three isozymes of PEPCK; 
Mycobacterium tuberculosis, rat cytosolic, and human mitochondrial.  These three enzymes are 
all GTP-dependent enzymes with conserved active sites.  It is expected that CMP will bind 
across the competitive OAA/PEP active site and adjacent secondary binding pocket in all three 
of the tested isozymes.  Structural and kinetics characterization will be used to give insight into 
the degree and mechanism of inhibition of PEPCK by CMP.  
 
 
 
 
 
 
 
 
 
 
 
39 
 
Materials & Methods – Part 7: Protein Expression and Purification 
7.1: Expression of Isozymes rcPEPCK & mtbPEPCK  
Expression of rcPEPCK started with overnight cultures of BL21(DE3) E. coli with pET-SUMO 
vector containing the rcPCK gene.  These cells were grown overnight at 37°C at 200rpm in LB 
media with kanamycin antibiotic at a concentration of 50µg/mL.  The overnight culture was 
centrifuged for 10 minutes at 5000g.  The resultant pellet was resuspended in fresh ZYP-5052 
media.  The resuspended pellet was transferred into four, 1L cultures of ZYP-5052 with 
50µg/mL of kanamycin.  The cultures were then incubated at 37°C at 200rpm for 16-20 hours.  
The cultures were then centrifuged at 7000g for 20 minutes, and the resultant pellets were 
frozen at -80°C.  
 
7.2: Expression of hmPEPCK  
The human mitochondrial isozyme (hmPEPCK) was expressed in BL21 (DE3) cells with pET-
SUMO vector via IPTG induction.  The four, 1L cultures were grown in LB media at 37°C until an 
OD600 of approximately 1.2.  The temperature is then dropped to 20°C for 30 minutes.  The 
cultures are induced with 0.1mM IPTG and express for 16-20 hours at 20°C. Cells are pelleted 
and frozen in the same manner as the rat cytosolic and M. tuberculosis expressions.   
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7.3: rcPEPCK Purification for Kinetics and Crystallography 
All purification steps were completed at 4°C.  The frozen pellets were extracted from their 
containers and resuspended in Buffer 1, refer to table 7.1, until a final volume of approximately 
50mL. The homogenous solution was then loading to a prechilled French Press cell (4°C) and the 
cells were lysed at 20000 PSI twice.   The lysed cells were then centrifuged at 12000g for 30-45 
minutes to pellet the insoluble fraction.  The supernatant was then removed and added to 
Qiagen Nickel-NTA resin pre-equilibrated in Buffer 1.  The resin/supernatant combination was 
then mixed for 1 hour at 4°C. The resin was then washed with Buffer 1 until the flow through 
A280 was less than 0.1.  Buffer 2 was the introduced to the resin to eluted the SUMO-fused 
protein.  Fractions were collected and absorbance’s were checked to determine which fractions 
held protein.  These fractions were then concentrated with a 50mL Amicon Stirred Cell Nitrogen 
Spin Concentrator with a 30kDa Amicon HA-filter to a final volume of approximately 10mL.  This 
protein solution was then incubated with SUMO-protease to liberate the SUMO-fusion tag 
overnight at 4°C.  The resultant solution was buffer exchanged on a Bio-Rad P6DG 
polyacrylamide gel column which has Chelex-100 added to chelate contaminating metal ions, 
and pre-equilibrated in Buffer 3.  The protein digest solution was added to the column, and 
fractions were taken.  Fractions were checked spectrophotometrically again at 280nm, and 
fractions containing protein were concentrated to 10mL.   This solution was then added to the 
Qiagen Nickel-NTA resin again that had been pre-equilibrated in Buffer 3.  The protein/nickel 
was mixed for 1 hour to bind the SUMO-fusion tag.  The solution was allowed to flow through 
and collected in fractions.  The resin was then washed in Buffer 3 into fractions and all fractions 
containing protein were concentrated to 10mL.  The now cleaved rcPEPCK was buffer 
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exchanged into buffer 4 via P6DG column pre-equilibrated in buffer 4.  Fractions were collected 
of the protein sample now buffer exchanged in buffer 4, and they were concentrated down to a 
working concentration of 10-20mg/mL.  The protein was then flash frozen in liquid Nitrogen in 
20µL aliquots.  The frozen protein was stored in a -80°C freezer.  Purity was qualitatively 
assessed by SDS-PAGE.  
 
7.4: mtbPEPCK Purification for Kinetics 
The recombinant Mycobacterium tuberculosis PEPCK enzyme purification was the completed 
without deviation as stated above in the rcPEPCK.  The differences between the two 
purification was that addition of 1mM EDTA and 0.1mM PMSF in the initial buffer 1. After the 
lysis and centrifugation to pellet the insoluble fraction, ammonium sulfate was added to the 
supernatant to a final saturation of 65%.  The ammonium sulfate precipitation was stirred at 
4°C overnight.  The precipitation was then centrifuged at 12000g for 15 minutes.  The pellet 
was resuspended in Buffer 1 without protease inhibitors (EDTA/PMSF).  
 
7.5: hmPEPCK-SUMO Fusion Purification for Kinetics 
The recombinant Human mitochondrial PEPCK purification was completed in the same manner 
as mtbPEPCK.  The only deviation was the purification was completed after the initial Nickel-
NTA and subsequent buffer exchange into Buffer 4.  The enzyme was still fused to the SUMO-
tag to help with solubility and stability. 
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Table 7.1: Purification Buffers for all kinetic protocols.   
 
All buffers were made a day prior to purification, and reducing agent was added immediately 
prior to starting.  
 
7.6: hmPEPCK Purification – Cleaved 
It has been a goal of mine of mine to optimize the purification protocol for the human 
mitochondrial PEPCK.  This has been an effort in hopes for crystallographic structural work, 
increased yields and purity for biochemical analysis.  In this new protocol, the purify is much 
higher then previous stated in section 1.5, but the yield is much lower.  For basic kinetic 
analysis, the purification in section 1.5 is satisfactory, but a new protocol is necessary for 
different testing.  
All purification steps were completed at 4°C.  The frozen pellets were resuspended in buffer 5 
and stirred to create a homogenous mixture.  0.1mM EDTA, 0.1mM PMSF, and finally 1mL of 
Calbiochem Protease Inhibitor Cocktail 7 was added to prevent proteolysis during the initial 
stages of purifications. The solution was then loaded into a prechilled French press cell (4°C) 
and the cells were lysed at 20000PSI, twice.  The lysis was then centrifuged for 30minutes at 
12000g. The supernatant was removed from the insoluble pellet and ammonium sulfate was 
Buffer HEPES (mM) pH 7.5 NaCl (mM) Imidazole (mM) Glycerol (%) Reducing Agent 
#1 25 300 10 10 2mM TCEP 
#2 25 0 300 0 2mM TCEP 
#3 25 0 0 0 2mM TCEP 
#4 25 0 0 0 10mM DTT 
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added to a final concentration of 65%.  The ammonium sulfate precipitation was incubated 
overnight at 4°C.  The ammonium sulfate precipitation was centrifuged at 12000g for 15 
minutes.  The supernatant was removed and the pellet was resuspended in buffer 1 without 
EDTA, PMSF, or Cocktail 7.  The solution was added to pre-equilibrated Nickel-NTA resin from 
Qiagen, and the protein solution/Nickel-NTA was incubated for 1 hr at 4°C.  The resin was 
washed with buffer 1 until the flow through A280 was below 0.1, at this point buffer 6 was used 
to elute the SUMO-fused hmPEPCK from the nickel resin.  Fractions were collected, and 
fractions containing protein were concentrated with a 30kDa cutoff Amicon HA-filter to 
approximately 10mL.  The resultant solution was buffer exchanged on a Bio-Rad P6DG 
polyacrylamide gel column which was chelexed and pre-equilibrated in Buffer 7.  Fractions were 
collected and enzyme containing fractions were concentrated to approximately 4-5mL.  The 
enzyme containing solution was added to Ceramic Hydroxyapatite type 2, 20µm resin via a 
FPLC.  The protein was then eluted with a gradient of 5-400mM KPO4- (buffer 7-8).  Fractions 
are checked for SUMO-fused hmPEPCK via SDS-PAGE, and concentrated to 10mL.  A second 
buffer exchange into buffer 8 via P6DG desalting column and concentrated again to 10mL. One 
aliquot of SUMO-protease is added to the solution and left overnight at 4°C to remove the 
SUMO-tag.  Flocculation is seen, with major loss of PEPCK precipitation.  The resultant soluble 
cleaved enzyme is incubated for 1 hour at 4°C with pre-equilibrated Nickel-NTA resin.  Flow-
through is collected, and the resin is washed with buffer 7.  All fractions with A280 above 0.1 
were concentrated to 10mL.  The solution was then buffer exchanged a final time into buffer 9.  
The buffer exchanged protein solution was concentrated to a stock concentration of 10mg/mL, 
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and flash-frozen in liquid nitrogen in 20µL aliquots.  Final purity was checked via SDS-PAGE 
(Figure 10.1). 
 
Table 7.2:  Purification buffers for hmPEPCK purification to get a highly purified monospecies. 
 
 
 
 
 
 
 
 
 
 
 
Buffer 
KPO4- (mM) pH 
6.8 
NaCl 
(mM) 
Imidazole 
(mM) 
Glycerol 
(%) 
Reducing 
Agent 
#5 5 300 10 10 2mM TCEP 
#6 5 0 300 0 2mM TCEP 
#7 5 0 0 0 2mM TCEP 
#8 400 0 0 0 2mM TCEP 
#9 5 0 0 0 10mM DTT 
45 
 
Materials and Methods - Part 8: Kinetic Assays 
8.1: PEP  OAA – Dephosphorylation and Carboxylation  
The enzymatic activity and inhibition assays were determined by evaluating various 
concentrations of inhibitor as well as substrate.  The reaction was measured at 340nm in a Cary 
100 UV spectrophotometer by the oxidation of NADH at 25°C.  The corresponding kinetic values 
were calculated based off of data obtained in the anaplerotic reaction, the conversion of 
phosphoenolpyruvate to oxaloacetic acid. The reaction mixture contained 50mM HEPES pH 7.5, 
10mM DTT, 100µM MnCl2, 4mM MgCl2, 1mM GDP, 300µM NADH, 50mM KHCO3-, 10 units of 
MDH, and 2.5µg of PEPCK, with varying concentrations of PEP from 10-4000µM. The reaction 
was measured with the addition of both PEPCK and MDH simultaneously.  The reaction 
mixtures were incubated at 25°C for a minimum of 5 minutes to ensure steady temperature.  
Human mitochondrial PEPCK was incubated with 5% Chelex 100 for 1 hour, followed by 
subsequent centrifuge and filtering.  100mM KHCO3- was also used for all assays against human 
mitochondrial PEPCK.  
 
8.2: IC50 Determination 
The IC50 values were determined by evaluating enzyme activity with fixed substrate 
concentration, and varying inhibitor concentration.  The assay mixture was fixed at 500uM PEP, 
and all other assay conditions are same as section 8.1.  GraphPad Prism 8 software was used to 
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create plots and calculated IC50.  From IC50, Ki were determined from the Database Resource for 
Clostridial Neurotoxins algorithm, fitting to the equation 12.3. 
 
8.3: Data Analysis 
All data analysis was completed with SigmaPlot11 with the Enzyme Kinetic module.  All of the 
data were fit to equation 1, and respective Km and Vmax values were used to create replots of 
Km/Vmax and 1/Vmax to determine the Ki values of CMP against the various isozymes studied.  
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Materials and Methods – Part 9: Structural Studies 
9.1: Crystallization of rcPEPCK 
Co-crystallization of CMP with rcPEPCK was completed by setting hanging drops of mother 
liquor containing 0.1M HEPES pH 7.5, 24-34% PEG 3350, 0.5µL of 5mM CMP, and 0.5µL of 
10mM MnCl2, and varying amounts of rcPEPCK (~10mg/mL). Various drops size/ratios were 
used from 2:2, 2:4, and 4:2 (protein to mother liquor in uL) were equilibrated over 1-3 days 
until crystals were formed.  Crystals were harvested and cryoprotected in 0.1M HEPES pH 7.5, 
35% PEG 3350, 10%PEG 400, 2mM MnCl2, and 1mM CMP.  These cryoprotected crystals were 
then flash frozen in liquid nitrogen for long term storage. 
 
9.2: Data Collection 
Cryocooled crystals were sent to the CMCF Beamline 08ID-1 at the Canadian Light Source in 
Saskatoon, Saskatchewan.  Data was indexed, scaled, and integrated using HKL2000. 
 
9.3: Determination and Refinement 
rcPEPCK_CMP was solved with molecular replacement using MOLREP in CCP4 with the 
previously solved structure of PEPCK_Mn2+ PDB ID#2QEW.  The structure was refined with 
Refmac5 and manual building in COOT. Water validation was completed through COOT.  
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Results - Part 10.1: Kinetic Analysis of CMP 
Kinetic characterization were all completed using the assays outlined in section 8.1.  The results 
are tabulated in Table 10.1, and the Ki values presented are taken from the Km/Vmax vs [I] replot.  
The Ki values determined were 29+/-2.8uM, 54.8+/-3.0uM, and 83.4+/-8.0uM for the rat 
cytosolic, Mycobacterium tuberculosis, and human mitochondrial PEPCK respectively.   
 
Table 10.1: Kinetic Characterizations of CMP and PEPCK       
Enzyme 
Ki from 
Replots 
(uM) 
Ki From Fits 
(uM) Mode of Inhibition 
Rat Cytosolic 29.0+/-2.8 11.8+/-1.4 Competitive 
Mycobacterium Tuberculosis PEPCK 54.8+/-3.0 45.7+/-3.5 Competitive 
Human Mitochondrial 83.4+/-8.0 46.0+/-9.3 Competitive 
 
IC50 characterizations were completed using assay outlined in section 8.2.  The results are 
tabulated below in Table 10.2.  Each of the IC50 values were taken and an expected Ki was 
determined.  These Ki values are 3.8+/-0.5uM for human mitochondrial PEPCK vs 3-MPA, 
57.9+/-7.2uM for human mitochondrial vs CMP, and finally 35.9+/-9.7uM for Rat cytosolic vs 
CMP.   Full curves can be seen in the appendix. 
 
 
Table 10.2: IC50 Characterizations             
Enzyme & Inhibitor IC50 (uM)   Calculated Ki  Goodness of Fit R2 
3-MPA vs Human Mitochondrial 7.5+/-0.6  3.8+/-0.5 0.99 
CMP vs Human Mitochondrial 115.7+/-9.6  57.9+/-7.2 0.99 
CMP vs Rat Cytosolic 107.8+/-27.2  35.9+/-9.7 0.97 
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10.2: Purification of hmPEPCK 
The complete purification protocol for human mitochondrial PEPCK optimized to create a 
monospecies for further structural studies.  Figure 10.1 below shows SDS-PAGE at various steps 
of the purification protocol.  
 
 
  
 
 
 
 
Figure 10.1: SDS-PAGE to check the purity of the human mitochondrial PEPCK.  Lane 1 is lysate, 
lane 2 is after nickel chromatography, lane 3 is after CHT chromatography, and finally lane 4 is 
after SUMO digest and second nickel chromatography.  
 
 
After SUMO digestion, and binding to the nickel-NTA resin, there is major precipitation of 
protein.  As seen from lanes 3 and 4, there is a high level of purity that can be obtained.  
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10.3: Structural Determination of rcPEPCK-CMP 
The cocrystallized structure of rcPEPCK and CMP was determined, with all data statistics 
present in the appendix.  There is excellent electron density in part due to the high-resolution 
of the data (1.5Å), and therefore CMP was modelled very easily.   In summary, the space group 
is P21, with resolution limits of 59.4-1.49Å and redundancy of 4.8.  A complete dataset was 
collected of 360° in 1° increments.    
 
 
 
 
 
 
 
 
 
 
51 
 
 
Figure 10.2: CMP bound to active site manganese M1 metal (purple).  The P-loop and R-Loop are 
both coloured in green and red respectively, while atoms are coloured by type.  All binding 
residues are also highlighted. CMP is modeled into the experimental electron density (blue, 2Fo-
Fc, rendered at 1.5 sigma). The resolution of structure is 1.5Å. Image was rendered in CCP4MG.  
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Discussion – Part 11: Inhibition of PEPCK by CMP 
11.1: 3-Mercaptopicolinic acid and Its History of Inhibition 
PEPCK’s role in metabolic homeostasis, and its new emphasis in various clinical maladies makes 
the enzyme a very attractive therapeutic target.  By specifically targeting PEPCK, conclusions 
can be drawn with regards to its specific role.  Crystal structures of the various PEPCKs have 
only been available in the last 20 years but many studies determining inhibitors of 
gluconeogenesis, and specifically PEPCK, have been completed since the 60’s.  A combination of 
both structural work, and inhibition studies are now finally starting to elucidate molecular 
scaffolds that can be used to build more potent and selective inhibitors. Of these initial 
inhibitors studies, tryptophan and its metabolites were determined to have an effect on PEPCK 
turnover.45,50,64  Saunders et al determined that 3-mercaptopicolinic acid was a novel inhibitor 
of gluconeogenesis.8  A year later, non-competitive inhibition of PEPCK with 3-
mercaptopicolinic acid was seen in both mitochondrial and cytosolic fractions, with the 
cytosolic enzyme being more potently inhibited.47   With the confirmation that 3-
mercaptopiconlinic acid inhibits PEPCK, a mechanism of action had to be determined.  Baum, 
Schramm, and Hanson in 1975 proposed a mechanism for the non-competitive inhibition 
pattern.  They proposed that 3-mercaptopicolinic acid was acting by chelating the M1 
manganese ion from the active site of the enzyme.26 In contrast to the chelation theory, Nowak 
and Makinen suggested that 3-mercaptopicolinic acid may bind in an overlapping binding site, 
resulting in an unfavourable conformation change.35  This accounts for the Km and Vmax effects 
seen in their inhibition studies, but they could not rule out the idea that 3-mercaptopicolinic 
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acid also bound to a secondary allosteric site.35  With an unconfirmed mechanism, 
crystallographic data was required to fully explain this mixed inhibition.  Holyoak and his 
colleagues published this structural and kinetic work determining that 3-mercaptopicolinic acid 
actual bound in two different sites, at the active site and a second behind the P-loop of PEPCK, 
Figure 11.1.2 
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Figure 11.1: 3-MPA bound to both the active site in a competitive fashion (left), and the 
secondary allosteric binding pocket (right) generated from PDB ID#4YW8.  The P-loop is 
highlighted in green, while the 3-MPA molecules are covered in mesh.  
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11.2: Further Inhibitory Studies and Adjacent Binding Cleft 
The need for more selective inhibitors would allow for targeted inhibition of PEPCK, resulting in 
an elevated understanding of metabolism, various biomedical maladies, and enzymology.  In 
2008, the Holyoak lab conducted various screens against rat cytosolic PEPCK and prospected 
inhibitors.54  Of these inhibitors, a few had very low Ki values and one in particular had an 
interesting mechanism of inhibition. The inhibitor, sulfoacetate, is of particular interest to the 
work within this body.  Through crystallographic data, sulfoacetate was shown to bind in a 
neighbouring adjacent pocket to the PEPCK active site M1 metal with a Ki of approximately 
85uM.54  This new pocket opens only with the movement of Y235 away from the active site, 
and towards the interior of the PEPCK.  This rotation is seen after OAA has been decarboxylated 
and has been phosphorylated to form PEP.  Sulfoacetate forms an edge on interaction with 
Y235, stabilizing them into the new cleft (Figure 11.2).54 
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Figure 11.2: Mechanism of inhibition of sulfoacetate from PDB ID#2RKE.  Please note Y235 is 
rotated into the PEP-bound orientation and sulfoacetate is highlighted in mesh.  
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11.3: Inhibition of PEPCK: Conception of Carboxymethyl-thiol-picolinic 
Acid 
Based on the 3-mercaptopicolinic acid work and the sulfoacetate inhibition mechanism, the 
question arises if both the active site competitive inhibition mechanism can be exploited in 
conjunction with this new adjacent binding pocket.55 From the scaffold of 3-mercaptopicolinic 
acid a new molecule was created, carboxymethyl-thio-picolinic acid (CMP).  By extending the 
sulfhydryl tail of 3-mercaptopicolinic acid with a carboxyl group, the aim is to have an increase 
selective inhibition of PEPCK.  Figure 12 indicates superimposed images of 3-mercaptopicolinic 
acid inhibition with sulfoacetate. As can be seen, the overlapping sulfur atoms of both groups 
allow for a possible bridge between the two inhibitors.   
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Figure 11.3: Superimposion of PBD ID# 4YW8 and 2RKE.  3-mercaptopicolinic acid is the 
molecule in green, while sulfoacetate is in orange.  Also note, that Y235 is in the PEP-bound 
orientation, allowing for sulfoacetate to bind. 
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Figure 11.4: Molecular structures of potential inhibitors of PEPCK.  A, tryptophan, B, 3-
mercaptopicolinic acid, C, sulfoacetate, and D, carboxymethyl-thiol-picolinic acid.  
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11.4: Inhibition of PEPCK by CMP 
The focus of this project was to create a more selective inhibitor for PEPCK, by simultaneously 
occupying the OAA/PEP active site, as well as an adjacent secondary sulfoacetate binding 
pocket (Figure 11.2).  The addition of the carboxymethyl tail onto the sulfhydryl of 3-MPA 
would potentially create a molecule that could inhibit PEPCK through this new mechanism.  The 
structural insight from the cocrystallization of CMP to the rat cytosolic PEPCK shows that CMP 
does bind to PEPCK, concurrently occupying the OAA/PEP and the adjacent site as predicted.  
This inhibition mechanism is proposed to occur in all PEPCK because of the enzymes highly 
conserved active site.  Seen in figure 11.5, CMP binds in coordination with the M1 manganese 
metal in the same position as 3-MPA with the nitrogen and carboxyl of picolinic acid, while 
CMPs carboxy tail extends into the PEP binding region. This is the same position and 
mechanism that was hypothesized for CMP.  
Figure 11.6 shows the various residues of the active site and their interaction with CMP.  All 
binding residues are conserved from 3-MPA and CMP.  Because of the extension of the carboxy 
tail, an additional residue A403 can now interact with CMP.  When PEP is bound to the active 
site, A403 amide and backbone nitrogen interacts with O2 at distance of 2.9 Å through H-
bonding.25 As seen in figure 11.6, this binding pattern is conserved.  Structural overlaps (data 
not shown) between rcPEPCK-CMP and PEP bound PEPCK (PDB ID# 4GMW), show the 
orientation of A403 and Y235 are completely conserved.  
The addition of the carboxy tail moiety also removes the allosteric effect that 3-MPA exhibited 
against rat cytosolic PEPCK.  The size and length of CMP would prevent it from binding behind 
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the P-Loop, and the added protection of the reactive thiol by the carboxy tail extension 
prevents covalent disulfide binding to C288 shown when MPA bind in the allosteric pocket.2 
 
 
 
 
 
 
 
62 
 
 
Figure 11.5: Structural overlap of rcPEPCK-CMP (tan) and PDB ID#4YW9 (light blue).  CMP is 
shown to overlap with 3-MPA at the active site.  The rotation of Y235 from the open position to 
the closed position.  The hydroxyl of tyrosine appears to move ~4.8 Å to make space for the 
carboxy tail moiety of CMP. 
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Figure 11.6: rcPEPCK-CMP with all binding residues that interact with CMP.  E403 appears to 
interact with a carboxyl oxygen of the carboxy tail as proximity is measured to ~2.9 Å. 
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With the exact position and mechanism of CMP’s inhibition determined through the structural 
work, the potency of the interaction was determined through inhibition assays.  CMP was 
assayed against the various isozymes of PEPCK to determine an experimental Ki value.  This Ki 
will represent the potency of inhibition and further explain the inhibition pattern seen in the 
structural work.  The Ki values listed in table 10.1 were all taken from K/V vs [I] replots, as well 
as from the full set of curves fitted to a competitive model.  The 1/V vs [I] replot (see appendix) 
for all of the inhibition assays show that there is a small intercept effect present, as the Vmax 
decreases slightly. This can be attributed to a partial chelation effect of CMP for M1 metal ions.  
This would effectively reduce the overall amount of competent enzyme able to bind and 
catalyse substrate, decreasing the Vmax.  This behaviour is also seen with 3-MPA and other 
picolinic acid derivatives.2 This chelation effect changes the inhibition model from a competitive 
one as seen from the structural work, to a mixed inhibition model.  The inherent problem with 
using a mixed inhibition model for documenting inhibition constants is at low concentrations of 
CMP, there is very little attributable chelation, but at high concentrations this effect is more 
drastic.   This interesting mode of inhibition will cause inaccuracies in fitted data, whereas the 
replot may more accurately reflect the inhibition constants.  For this reason, in conjunction with 
the structural data presented a competitive inhibition model was used for the global fits.  
Lastly, the Ki values from the K/V vs [I] replots were used for analysis and discussion of the 
inhibition potency.   
Based on the conservation of PEPCK’s active site, the overall inhibition mechanism and potency 
should be comparable across each of the isozymes tested with only minor variations because of 
specific enzyme dynamics.  With conservation of the active sites and the minor differences in 
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potency, there should be an inability to selectively inhibit one isozyme of PEPCK while leaving 
the others unaffected.  When examining the relative inhibition of CMP to each of the isozymes, 
they are all selectively inhibited based on structural work and active site conservation but there 
is a small decrease in potency (30uM, 50uM to potentially 83uM for rat cytosolic, 
Mycobacterium tuberculosis and human mitochondrial PEPCK respectively).  Although not 
greatly significant, it is interesting nonetheless that there is 2-3 fold difference in inhibition 
between rat cytosolic and human mitochondrial PEPCK.  To better understand this slight 
difference in potency structural work on the human mitochondrial isozyme will have to be 
completed, so the conformational dynamics of the enzyme can be understood.  
Under the assumption that the Ki values documented in table 10.1 are accurate representations 
of the binding constants of CMP, conclusions can be drawn with regards to the conformational 
dynamics of each isozyme.  Although the active sites are conserved, the rest of the enzyme is 
variable.  These structural variations are necessary for the enzyme to adopt differing 
conformations, some that are productive while others are not.58   Enzymes are dynamic systems 
that will sample all conformations at varying rate.  This differing sampling rate between 
productive and non productive conformers between isozymes will create different population 
distributions.58 These average population distributions influence the rate of substrate binding 
of the enzyme, which will influence kinetic binding constants.58   The omega-loop is one 
influence in the differential conformational population distributions as it must be open to allow 
for substrate binding.  Once PEPCK has encountered substrates in a productive conformation, 
many dynamic transitions from unordered to ordered state must occur for the enzyme to 
commit to catalysis.58  The motion of the omega-loop to a closed state after substrate binding is 
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required for catalysis to occur.25,58  Upon closure of the omega-loop the dielectric constant of 
the active site will decrease as water is removed, harbouring tighter binding of the 
substrates/inhibitors to the enthalpic residues through increased electrostatic interactions.25  If 
the omega-loop across the isozymes transition from open to closed states at differing rates 
between isozymes, the binding constants will vary.  Sullivan and Holyoak in 2008 showed that 
even during the Michaelis complex, there is a propensity for the omega-loop to occupy an open 
state (~20%).58 The omega-loop shows that isozymes having dynamic variation in both: 
population shifts of productive and non-productive conformers that allow for substrate binding, 
as well as rate of conformation shifts to catalytically competent conformers to orient substrates 
to commit to catalysis.  PEPCK’s system of conformational dynamic is still more complex, but 
this example reinforces the idea that isozymes can have different kinetic parameters even with 
all catalytic binding residues being conserved.  This could be an explanation for the different Ki 
observed between the isozymes tested and CMP. 
Unfortunately, the Ki value (83uM) documented for human mitochondrial PEPCK is only an 
approximation as a full inhibition curve could not be completed.  There was not enough CMP 
available to complete the higher concentration points for CMP.  More CMP will be synthesized 
in the future to complete the inhibition data.  
In light of this approximation, IC50’s and the corresponding Ki were determined for human 
mitochondrial PEPCK.  The Ki determined is approximately 58uM and the accuracy of my IC50 
determination was validated by testing the IC50 for CMP against rat cytosolic PEPCK. The Ki of 
CMP for rat cytosolic PEPCK from IC50 determination (36uM) was quite similar to that 
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determined through complete kinetic analysis (30uM), showing strong correlation of IC50 
determined Ki and the inhibitory constants found from complete inhibition curves.  
When comparing the inhibitory effect of CMP and 3-MPA, 3-MPA was shown to have a Ki of 
approximately 10uM against the rat cytosolic PEPCK (competitive site). In contrast, CMP has a Ki 
of 30uM.  This small decrease in inhibition may be caused by the free energy landscape 
changing.  Both enthalpic and entropic contributions effect binding affinities of small ligands to 
proteins through Gibbs’ free energy.  Based on the structural information for rcPEPCK-CMP, the 
overall enthalpic contributions should increase as now an additional residue, A403, will interact 
with CMP.  To offset this new enthalpic energy that is gained, the entropic penalty of the 
carboxy tail will lower the free energy of the system.  Due to the decrease in binding affinity, 
the entropic penalty must be greater than the enthalplic energy contribution.  There is no 
information on the inhibitory constant of 3-MPA and the Mycobacterium tuberculosis PEPCK, 
but due to the conserved active site, it is probably similar to the Ki of 3-MPA and rat cytosolic 
PEPCK.   
Last, because of expected Ki of CMP for human mitochondrial PEPCK is potentially 2-3 times 
higher than the other two isozymes tested, the binding affinity for 3-MPA for this isozyme was 
also determined. This was investigated to see if there was an inherent difference in the 
inhibition of human mitochondrial PEPCK for 3-MPA and other picolinic acid derivatives.  This 
inherent difference could manifest itself through varying Ki value.  Once calculated the Ki was 
determined to be 3-4uM, showing tighter binding of 3-MPA by 2 fold more than the rat 
cytosolic inhibition.  This tighter binding of 3-MPA for human mitochondrial PEPCK may be an 
artifact of 3-MPA binding to both the competitive site and the allosteric site.   These two 
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binding locations for 3-MPA could compound to cause a greater inhibitory effect and decrease 
in Ki.  These similar Ki documented for CMP may have a lower binding affinity for human 
mitochondrial PEPCK because a slower conformational shift to a state readily available for 
inhibition by CMP.    The dynamic difference causing a change in Ki could be in the PEP binding 
pocket, and in relation to Y235.  This difference would not manifest itself in inhibition of PEPCK 
by 3-MPA, but would with the mechanism of CMP.  Structural information on human 
mitochondrial PEPCK is required to validate this hypothesis.   
In closing, the structural and kinetic work clearly shows the new inhibition mechanism of CMP.  
CMP binds by bridging the OAA/PEP binding site and the adjacent secondary CO2 binding site, 
and this mechanism should be preserved in all PEPCK isozymes based on active site 
conservation.  The potency of CMP shows variation across isozymes tested, with the greatest 
difference of 2-3 fold between rat cytosolic (Ki ~30uM) and human mitochondrial (Ki ~83uM).  
Although not greatly significant, this may indicate dynamic conformational differences between 
these two isozymes.  
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Conclusion and Future Directions: 
The need for highly selective inhibitors of PEPCK is apparent, as PEPCKs inhibition could be used 
to further our understanding metabolism as a whole and the various maladies PEPCK has been 
implicated in.  From initial inhibition studies tryptophan metabolites, and more specifically 3-
mercaptopicolinic acid, showed potent inhibition of all PEPCK isozymes based on the 
conservation in the active site.  Based on structural and inhibition studies, carboxymethyl-thiol-
picolinic acid was designed to improve the scaffold of 3-MPA to create a more selective, and 
hopefully potent, inhibitor of PEPCK that can bind both the OAA/PEP active site as well as a 
secondary adjacent binding site simultaneously.  The work presented here shows a slight 
decrease in potency (10uM and 30uM Ki inhibition for 3-MPA and CMP respectively), but 
hopefully increases selectivity as a secondary adjacent binding site is now utilized by CMP.   
With the new crystallographic structures of PEPCK, the active site architecture can be exploited 
when creating new inhibitors for PEPCK.  Although 3-mercaptopicolinic acid has been shown to 
be a more potent inhibitor, CMP should in theory be a more selective inhibitor as it now utilizes 
a secondary binding pocket.  From the new scaffold of CMP, modifications could be introduced 
to extend the molecule into other areas of the active site.  Although this work has shown the 
potency and mechanism of action, in vivo studies are necessary to determine the efficacy of the 
inhibitor.  This inhibitor could be used against various cancer cell lines, Mycobacterium 
tuberculosis, as well as human mammalian cells.  Based on the structural conservation of the 
PEPCK active site, there should not be a great difference in potency across PEPCK isozymes, but 
its selectivity for PEPCK could be tested.  
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There has also been a call within literature for a greater understanding of the human 
mitochondrial PEPCK, as its function and purpose has still not fully been defined.  This work 
contributes to this as it identifies a potential difference in inhibition potency between the 
cytosolic and mitochondrial PEPCK.  Structural insight would be a great help in elucidating the 
questions surrounding human mitochondrial PEPCK.  
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Appendix: 
Equations: 
∆𝑮 = −𝑹𝑻𝒍𝒏𝑲𝒊 =  ∆𝑯 − 𝑻∆𝑺  
Equation 12.1 – Gibbs free energy. ∆𝐺 is change in free energy, R is ideal gas constant, T is temperature, 
Ki is inhibition constant,∆𝐻 is change in enthalpy, and ∆𝑆 is change in entropy. 
 
𝒚 = 𝒎𝒊𝒏 +
(𝒎𝒂𝒙 − 𝒎𝒊𝒏)
𝟏 +
𝒙
𝑰𝑪𝟓𝟎
 
Equation 12.2 – Determination of IC50.  Min and max are taken from experimental graph. Y and X are 
variables.  
 
𝑲𝒊 =
𝑰𝑪𝟓𝟎
𝟏 +  
[𝑺]
𝑲𝒎
 
Equation 12.3 – Determination of Ki from IC50 values to fit competitive model. [S] is substrate 
concentration, and Km is Michaelis binding constant 
 
𝝊 =
𝑽𝒎𝒂𝒙
𝟏 + (
𝑲𝒎
[𝑺]
)(𝟏 +
[𝑰]
𝑲𝒊)
 
Equation 12.4 – Fit to competitive model.  Vmax is maximal velocity, and [I] is inhibitor concentration. 
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𝝊 =
𝑽𝒎𝒂𝒙[𝑺]
𝑲𝒎 + [𝑺]
 
Equation 12.5 – Michaelis menten equation. 
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Inhibition of Rat Cytosolic PEPCK by CMP Fit To Competive Inhibition Model
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Inhibition of Mycobacterium Tuberculosis PEPCK by CMP Fit To Competive Inhibition Model
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Inhibition of Human Mitochondrial PEPCK by CMP Fitted to Competitive Model
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  rcPEPCK_CMP 
Wavelength (Å)  0.97952 
Space Group P21 
Unit Cell a=44.4 Å 
  b=118.7 Å 
  c=60.4 Å 
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  β=109.6 Å 
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No. of Unique Reflection 158815 
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Rmerge 0.08 (0.5) 
REFINEMENT   
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No. of ASU Molecules 1 
Rfree 0.177 (0.279) 
Rwork 0.153 (0.281) 
Average B Factor (Å2) - Protein 23.9  
Metals 22.8  
CMP 21.2  
Water   33.7 
Estimated Coordinate Error Based 
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Maximum Likelihood (Å)   
Bond Length Root-Mean-Square   
Deviation (Å) 0.02  
Bond Angle Room-Mean-Square   
 Deviation (°) 2.23  
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